Vertex Soars On Clinical Data And Boosts Biotech Stocks By: TalkMarkets March 29, 2017 at 22:00 PM EDT Vertex Pharmaceuticals soared over 20% to $108 on released Phase 3 clinical data for their cystic fibrosis drug. Read More >> Related Stocks: Aetna Alexion Pharmaceuticals Alnylam Pharmaceuticals Anthem Inc Cigna Corp Gw Pharma ADR HEALTHCARE Nasdaq Biotechnology Ishares ETF PowerShares QQQ Radius Recycling Inc Regeneron Pharmaceuticals S&P Biotech SPDR S&P Pharmaceuticals SPDR Vertex Pharmaceuticals